Key Points Production and onstream time continuing to show major progress Over 30 active trials underway. Successful commercialization news imminent, in our view We rate PCT shares Overweight with a USD18 per share...
Key Points Company hitting commercialization and production milestones Multiple customer trials in progress; first ever reported revenue logged We rate PCT shares Overweight, with a USD18 per share 12-month target price Summary PureCycle Technologies (PCT)...
Key Points Company hitting commercialization and production milestones Multiple customer trials in progress We rate PCT shares Overweight, with a USD18 per share 12-month target price Summary PureCycle Technologies (PCT) provided a Q4’24 update this...
Key Points Technology and scale-up concerns mostly allayed while capital raised. Product commercialization in 2025 could result in the next leg up in PCT shares First major product commercialization announcement (in 2025)...
Key Points Ironton facility continues to hit key production milestones Multiple customer trials in progress We rate PCT shares Overweight, with a USD16 per share 12-month target price Summary PureCycle Technologies (PCT) provided a Q3’24...
Key Points Capital raise, positive operations update, and clear near-term goals bode well for share price outperformance, in our view ASTS, while not a direct comparable, could provide insights into future PCT...
Key Points Record monthly production rates hit in June. No further outages foreseen at Ironton this year Compounding could provide further earnings boost We rate PCT shares Overweight, with a USD13 per share...
Key Points Fears around Ironton pellet production momentum slowing unfounded, in our view Recent plant improvements and CP2 system commissioning point to a pickup in pellet production momentum going forward We rate PCT...